About Baxalta
Baxalta is a company based in Chicago (United States) founded in 2015 was acquired by Shire in January 2016. Baxalta offers products and services including Oncology Medicines, Rare Disease Therapies, and Vaccine Products. Baxalta operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Chicago, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Takeda Pharmaceutical Company Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Shire
(Jan 11, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Baxalta
Baxalta offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Therapies, and Vaccine Products.
Treatments for cancer through innovative drug development
Solutions for immunology and metabolic disorders via clinical research
Infectious disease prevention through advanced manufacturing
People of Baxalta
Unlock access to complete
Unlock access to complete
Software Development Team
15 people
Leadership Team
7 people
Sales and Marketing
4 people
Legal and Compliance
3 people
Product Management Team
2 people
Global Team
2 people
Senior Team
2 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Baxalta
Detailed funding history for Baxalta
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Baxalta
Baxalta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Rare disease treatments are developed by a specialty biopharmaceutical firm.
|
Locked | Locked | Locked |
Investor details for Baxalta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Baxalta
Investment portfolio details for Baxalta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Baxalta
Detailed financials for Baxalta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Baxalta Comparisons
Peer comparison for Baxalta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Baxalta
Baxalta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Baxalta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Baxalta
Complete news archive for Baxalta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Baxalta
Baxalta was founded in 2015.
Baxalta is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Flemming Ornskov is the current CEO of Baxalta.
Baxalta was founded in 2015 and is headquartered in Chicago, United States. Therapies targeting orphan diseases and underserved conditions are developed, manufactured, and commercialized within the biotechnology sector. Operations center on hematology, oncology, and immunology, with a product pipeline featuring biologics that incorporate novel mechanisms and advanced technology platforms.
Baxalta's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Baxalta offers Oncology Medicines, Rare Disease Therapies, and Vaccine Products.
Baxalta has 1 investor. Key investors include Takeda Pharmaceuticals.